Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 3/20 | 0.39 |
| ▸ | S100A4 | P26447 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645032 | 0.86 | TSHR (0.45) | TSHRLMNAMAPTALDH1A1TDP1 | |
| SCHEMBL29929890 | 0.72 | LMNA (0.56) | TSHRLMNAMAPTMEN1NPC1 | |
| SCHEMBL57616 | 0.72 | LMNA (0.56) | TSHRLMNAMAPTMEN1NPC1 | |
| SCHEMBL10716598 | 0.72 | TDP1 (0.56) | TSHRMAPTMEN1RAB9AKMT2A | |
| SCHEMBL16338659 | 0.71 | TSHR (0.45) | TSHRLMNAMAPTMEN1KMT2A | |
| SCHEMBL8528988 | 0.71 | TSHR (0.42) | TSHRLMNAMAPTMEN1NPC1 | |
| SCHEMBL28122579 | 0.71 | TSHR (0.59) | TSHRLMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL31677837 | 0.71 | LMNA (0.54) | TSHRLMNAMAPTMEN1NPC1 | |
| SCHEMBL5167846 | 0.71 | LMNA (0.54) | TSHRLMNAMAPTMEN1NPC1 | |
| SCHEMBL2760792 | 0.71 | LMNA (0.54) | TSHRLMNAMAPTMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117983302-A | Catalyst containing ferrocene PNP ligand for ethylene selective tetramerization and preparation method and application thereof | 华东理工大学 | 2024-05-07 | — | — | CN | claimed |
| CN-117983302-A | Catalyst containing ferrocene PNP ligand for ethylene selective tetramerization and preparation method and application thereof | 华东理工大学 | 2024-05-07 | — | — | CN | disclosed |
| CN-107315318-B | Photosensitive composition | 东京应化工业株式会社 | 2022-07-01 | — | — | CN | disclosed |
| CN-107311889-B | Compound and method for producing same | 东京应化工业株式会社 | 2022-01-14 | — | — | CN | disclosed |
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | Sanford-Burnham Medical Research Institute California | 2012-04-19 | — | — | US | disclosed |
| EP-2433496-A1 | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification | Burnham Institute for Medical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| US-8119693-B2 | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2164329-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | The Burnham Institute for Medical Research (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | disclosed |
| WO-2009017863-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | TSHR 4282/4885LMNA 2775/4885MAPT 3950/4885 |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | TSHR 4282/4885LMNA 2775/4885MAPT 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.